OpenAlex
PricingAboutJobs
Log inGet started
Work

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

HTML

Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/j.1463-1326.2010.01355.x
Authors: M. C. Bunck, B. Eliasson, A. Cornér, R. J. Heine, R. M. Shaginian, M.‐R. Taskinen, H. Yki‐Järvinen, U. Smith, M. Diamant
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, Sahlgrenska University Hospital, Helsinki University Hospital, Minerva Foundation, Eli Lilly (United States), Eli Lilly (Netherlands)
Language: English

Topic: Bone health and osteoporosis research
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Keywords: exenatide, type 2 diabetes, bone mineral density, weight loss, incretin-based therapy, insulin glargine, metformin, calcium homeostasis, alkaline phosphatase, osteoporosis risk
SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, Amylin Pharmaceuticals
OpenAlex ID: W2097415450
FWCI: 6.294
Cites: 10
Cited by: 116
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security